Vasaloc (low-dose danazol) / Ampio - LARVOL DELTA

Low-Dose Danazol for the Treatment of Telomere Related Diseases (clinicaltrials.gov) - P2 | N=18 | Completed | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting ➔ Completed | Trial completion date: Oct 2027 ➔ Oct 2025 | Trial primary completion date: Apr 2027 ➔ Oct 2025

Trial completion • Trial completion date • Trial primary completion date • Neutropenia • DKC1 • RTEL1 • TERT

Low-Dose Danazol for the Treatment of Telomere Related Diseases (clinicaltrials.gov) - P2 | N=18 | Active, not recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Recruiting ➔ Active, not recruiting | N=40 ➔ 18

Enrollment change • Enrollment closed • Neutropenia • DKC1 • RTEL1 • TERT

Low-Dose Danazol for the Treatment of Telomere Related Diseases (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Trial primary completion date: Apr 2026 ➔ Apr 2027

Trial primary completion date • Neutropenia • DKC1 • RTEL1 • TERT

Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia. (PubMed, World Allergy Organ J) - "Many patients (mostly male) with milder disease had responded well to low-dose danazol with good tolerance and have continued to use it, whereas patients with higher disease burden are now using newer therapies, and overall satisfaction with current prophylaxis is high. Prevalence of HAE in South Australia aligns with international reports. Our population survey indicates that current long-term prophylaxis therapies including danazol, lanadelumab and C1-inhibitor, applied to appropriate patients taking into account disease activity and drug risks and tolerance, are effective for HAE attack prevention and produce high levels of satisfaction."

Journal • Cardiovascular • Complement-mediated Rare Disorders • Genetic Disorders • Hereditary Angioedema • Primary Immunodeficiency

Low-Dose Danazol for the Treatment of Telomere Related Diseases (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Apr 2026 ➔ Oct 2027

Trial completion date • TERT

REPHRASE: Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test (clinicaltrials.gov) - P=N/A; N=500; Not yet recruiting; Sponsor: Optina Diagnostics Inc.

New trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • MRI

"@TheADDF Start-up Forum: GraySpace Therapeutics https://t.co/aRlnOaoWCZ Imaginostics https://t.co/q03KuS3KnQ NeuroTherapi https://t.co/h7R3G8NipU Optina Diagnotics https://t.co/5aaawNiRBW Perha Therapeutics https://t.co/vVBRc5ce9D TauC3 Biologics https://t.co/UOGgroPpFT #Startups" (,@BRAINCURES)

Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging (clinicaltrials.gov) - P=N/A; N=4; Terminated; Sponsor: Center for Eye Research Australia; N=100 ➔ 4; Trial completion date: Dec 2020 ➔ Dec 2018; Recruiting ➔ Terminated; Trial primary completion date: Dec 2020 ➔ Dec 2018; The delay between diagnosis and initiation of treatment was no longer consistent with standard of care

Enrollment change • Trial completion date • Trial primary completion date • Trial termination